Empagliflozin 10 MG Clinical Trials
20 recruitingDrug
Phase 28Phase 47Phase 37Early Phase 11Not Applicable1
Showing 1–20 of 20 trials
Recruiting
Phase 4
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
HypertensionPre-Heart Failure
China National Center for Cardiovascular Diseases120 enrolled2 locationsNCT06055452
Recruiting
Early Phase 1
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
Chronic Kidney DiseasesPediatric Kidney Disease
Ann & Robert H Lurie Children's Hospital of Chicago40 enrolled1 locationNCT06430684
Recruiting
Phase 2
Empagliflozin in Patients With Cirrhosis and Ascites
CirrhosisLiver Failure
Yale University20 enrolled1 locationNCT05726032
Recruiting
Phase 3
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
Acute Heart Failure
Juntendo University444 enrolled69 locationsNCT05392764
Recruiting
Phase 2Phase 3
Empagliflozin Reversal of Arterial StiffnEss in Aging
Arterial StiffnessAging
University of Missouri-Columbia80 enrolled1 locationNCT06506422
Recruiting
Phase 2
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Non-Alcoholic Fatty Liver Disease
Justin Ryder40 enrolled1 locationNCT06355310
Recruiting
Phase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
NYU Langone Health60 enrolled2 locationsNCT05786443
Recruiting
Phase 3
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Cardiotoxicity
Maria Sklodowska-Curie National Research Institute of Oncology220 enrolled2 locationsNCT05271162
Recruiting
Phase 4
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Heart FailureAdult Congenital Heart Disease
Anita Saraf40 enrolled3 locationsNCT06260059
Recruiting
Phase 2Phase 3
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Empagliflozin in Cardiorenal Syndrome Type 1
Chulalongkorn University200 enrolled1 locationNCT06030843
Recruiting
Phase 2
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
End Stage Renal Disease on DialysisPeritoneal Dialysis ComplicationResidual Kidney Function+1 more
Chinese University of Hong Kong48 enrolled1 locationNCT06483074
Recruiting
Phase 4
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Chronic Kidney Diseases
Washington D.C. Veterans Affairs Medical Center60 enrolled1 locationNCT06110130
Recruiting
Phase 3
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Cardiogenic Shock
Central Hospital, Nancy, France164 enrolled8 locationsNCT05879276
Recruiting
Phase 4
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Chronic Heart Failure
Fazaia Ruth Pfau Medical College156 enrolled1 locationNCT06706791
Recruiting
Not Applicable
Efficacy of SGLT2 Inhibitors in Adults With Sepsis
SepsisInflammation
Hospital Authority, Hong Kong60 enrolled3 locationsNCT06473844
Recruiting
Phase 4
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
End Stage Renal Disease on Dialysis
Yale University30 enrolled1 locationNCT05671991
Recruiting
Phase 2Phase 3
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
Embolic Stroke of Undetermined SourceAtrial Fibrillation New Onset
University of East Anglia100 enrolled1 locationNCT06715449
Recruiting
Phase 4
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Heart FailureChronic Kidney DiseasesDiabetes Mellitus, Type 2
Herlev and Gentofte Hospital17,200 enrolled12 locationsNCT06642272
Recruiting
Phase 2Phase 3
The Role of SGLT2i in Management of Moderate AS
Moderate Aortic Valve Stenosis
University of East Anglia104 enrolled1 locationNCT06469645
Recruiting
Phase 4
Use of SGLT2i in noHCM With HFpEF
Hypertrophic CardiomyopathyHeart Failure With Preserved Ejection Fraction
China National Center for Cardiovascular Diseases94 enrolled1 locationNCT06401343